A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

NCT ID: NCT02167256

Last Updated: 2019-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 159 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2018-02-27

Brief Summary

AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models. This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification.

Conditions

Alzheimer's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AZD0530 100mg daily

Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of \<100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.

Group Type: EXPERIMENTAL

AZD0530 100mg daily

Intervention Type: DRUG

All patients in experimental group (50%) will be started on 100mg AZD0530 daily

AZD0530 125mg daily

Intervention Type: DRUG

Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.

AZD0530 Placebo

50% of patients will receive placebo treatment for the duration of the study,

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

50% of patients will receive placebo treatment for the duration of the study.

Interventions

AZD0530 100mg daily

All patients in experimental group (50%) will be started on 100mg AZD0530 daily

Intervention Type: DRUG

AZD0530 125mg daily

Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.

Intervention Type: DRUG

Placebo

50% of patients will receive placebo treatment for the duration of the study.

Intervention Type: DRUG

Other Intervention Names

saracatinib; saracatinib; saracatinib

Eligibility Criteria

Inclusion Criteria

1. NIA-Alzheimer's Association core clinical criteria for probable AD

2. 18F-Florbetapir scan with evidence of elevated Aβ (based on central review)

3. Age between 55-85 (inclusive)

4. MMSE score between 18 and 26 (inclusive)

5. Stability of permitted medications for 4 weeks. In particular:

• Stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 1 year)
• Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screen

6. Geriatric Depression Scale less than 6 [Note: a score ≥6 on this screening scale may be permissible, if the subject is examined by a site clinician and judged not to be depressed.]

7. Study partner is available who has frequent contact with the subject (e.g., average of 10 hours per week or more), and can accompany the subject to most visits to answer questions about the subject

8. Visual and auditory acuity adequate for neuropsychological testing

9. Good general health with no disease expected to interfere with the study

10. Subject is not pregnant, lactating, or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)

11. Modified Hachinski less than or equal to 4

12. Completed six grades of education or has a good work history

13. Must speak English or Spanish fluently

Exclusion Criteria

1. Any significant neurologic disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities

2. Screening/baseline MRI scan with evidence of infection, infarction, or other focal lesions or multiple lacunes or lacunes in a critical memory structure

3. Subjects that have any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker

4. Major depression, bipolar disorder as described in DSM-IV within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol

5. History of schizophrenia (DSM V criteria)

6. History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria)

7. Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study.

8. Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment

9. Clinically significant abnormalities in B12 or TFTs that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.

10. Residence in skilled nursing facility.

11. Use of any excluded medication as described in study protocol

12. Current or recent participation in any procedures involving radioactive agents, including current, past, or anticipated exposure to radiation in the workplace, such that the total radiation dose exposure to the subject in a given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1. This guideline is an effective dose of 5 rem received per year.

13. Neutropenia defined as absolute neutrophils count of <1,800/microliter

14. Thrombocytopenia defined as platelet count <120x103/microliter

15. For CSF sub-study participants, a current blood clotting or bleeding disorder, or significantly abnormal PT or PTT at screening

16. Clinically significant abnormalities in screening laboratories, including:

• Aspartate aminotransferase (AST) >1.5 times ULN
• Alanine aminotransferase (ALT) > 1.5 times ULN
• Total bilirubin >1.5 times ULN
• Serum creatinine >2.0 times ULN

17. History of interstitial lung disease

18. Patients whom the PI deems to be otherwise ineligible

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alzheimer's Therapeutic Research Institute

OTHER

Sponsor Role: collaborator

Yale University

OTHER

Sponsor Role: lead

Responsible Party

Stephen M. Strittmatter

Professor of Neurology and Neurobiology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Christopher H van Dyck, MD

Role: STUDY_DIRECTOR

Yale University

Paul Aisen, MD, PhD

Role: STUDY_DIRECTOR

USC Alzheimer's Therapeutic Research Institute (ATRI)

Locations

Barrow Neurological Institute

Phoenix, Arizona, United States

Banner Sun Health Research Institute

Sun City, Arizona, United States

University of California, Los Angeles

Los Angeles, California, United States

Yale Alzheimer's Disease Research Unit

New Haven, Connecticut, United States

Georgetown University

Washington D.C., District of Columbia, United States

Wien Center for Clinical Research/Mount Sinai Medical Center

Miami Beach, Florida, United States

University of South Florida - Health Byrd Alzheimer Institute

Tampa, Florida, United States

Northwestern University

Chicago, Illinois, United States

Rush University Medical Center

Chicago, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

University of Iowa

Iowa City, Iowa, United States

University of Kentucky

Lexington, Kentucky, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

University of Michigan, Ann Arbor

Ann Arbor, Michigan, United States

Mount Sinai School of Medicine

New York, New York, United States

University of Rochester Medical Center

Rochester, New York, United States

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pittsburgh, Alzheimer's Disease Research Center

Pittsburgh, Pennsylvania, United States

Roper St. Francis Hospital

Charleston, South Carolina, United States

University of Washington

Seattle, Washington, United States

University of British Columbia, Clinic for AD & Related Disorders

Vancouver, British Columbia, Canada

Countries

United States; Canada

References

Donohue MC, Langford O, Insel PS, van Dyck CH, Petersen RC, Craft S, Sethuraman G, Raman R, Aisen PS; Alzheimer's Disease Neuroimaging Initiative. Natural cubic splines for the analysis of Alzheimer's clinical trials. Pharm Stat. 2023 May-Jun;22(3):508-519. doi: 10.1002/pst.2285. Epub 2023 Jan 10.

Reference Type: DERIVED

PMID: 36627206 (View on PubMed)

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019 Oct 1;76(10):1219-1229. doi: 10.1001/jamaneurol.2019.2050.

Reference Type: DERIVED

PMID: 31329216 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

4UH3TR000967-02

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1404013830

Identifier Type: -

Identifier Source: org_study_id